Alzheimer's disease (AD) is a chronic disease that affects the elderly. There are many different types of dementia, but Alzheimer's disease is one of the leading causes of death. AD is a chronic brain disorder that leads to problems with language, disorientation, mood swings, bodily functions, memory loss, cognitive decline, mood or personality changes, and ultimately death due to dementia. Unfortunately, no cure has yet been developed for it, and it has no known causes. Clinically, imaging tools can aid in the diagnosis, and deep learning has recently emerged as an important component of these tools. Deep learning requires little or no image preprocessing and can infer an optimal data representation from raw images without prior feature selection. As a result, they produce a more objective and less biased process. The performance of a convolutional neural network (CNN) is primarily affected by the hyperparameters chosen and the dataset used. A deep learning model for classifying Alzheimer's patients has been developed using transfer learning and optimized by Gorilla Troops for early diagnosis. This study proposes the A3C-TL-GTO framework for MRI image classification and AD detection. The A3C-TL-GTO is an empirical quantitative framework for accurate and automatic AD classification, developed and evaluated with the Alzheimer's Dataset (four classes of images) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). The proposed framework reduces the bias and variability of preprocessing steps and hyperparameters optimization to the classifier model and dataset used. Our strategy, evaluated on MRIs, is easily adaptable to other imaging methods. According to our findings, the proposed framework was an excellent instrument for this task, with a significant potential advantage for patient care. The ADNI dataset, an online dataset on Alzheimer's disease, was used to obtain magnetic resonance imaging (MR) brain images. The experimental results demonstrate that the proposed framework achieves 96.65% accuracy for the Alzheimer's Dataset and 96.25% accuracy for the ADNI dataset. Moreover, a better performance in terms of accuracy is demonstrated over other state-of-the-art approaches.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185328PMC
http://dx.doi.org/10.3390/s22114250DOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
16
deep learning
12
proposed framework
12
transfer learning
8
gorilla troops
8
alzheimer's dataset
8
adni dataset
8
alzheimer's
7
dataset
7
learning
5

Similar Publications

Association of objective subtle cognitive difficulties with amyloid-β and tau deposition compared to subjective cognitive decline.

Eur J Nucl Med Mol Imaging

January 2025

Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.

Purpose: This study evaluated the differences in amyloid-β (Aβ), tau deposition, and longitudinal tau deposition between subjective cognitive decline (SCD) and objective subtle cognitive difficulties (Obj-SCD).

Methods: Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 234) and the Huashan cohort (n = 267) included individuals with Obj-SCD, SCD, subjective memory concern (SMC), and healthy controls (HC). General linear models (GLM) were used to compare baseline and longitudinal differences in Aβ and tau among the groups, and to examine the associations between these biomarkers.

View Article and Find Full Text PDF

Background: Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology.

Methods: We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493 as antibodies, a synthetic tau peptide as calibrator, and the Quanterix SP-X imager. Analytical validation performed in a College of American Pathologists-accredited CLIA laboratory involved multiple kit lots, operators, timepoints, and imagers.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is characterized by progressive memory loss and cognitive decline, significantly impairing the daily life of elderly individuals. The low abundance of blood-based biomarkers in AD necessitates higher analytical technique requirements. Herein, one novel iridium-based ECL self-enhanced nanoemitter (TPrA@Ir-SiO) was unprecedentedly reported, and it was further used to construct an ultrasensitive ECL magnetic immunosensor by a multiple-signal amplification strategy to unequally sensitively and accurately detect the AD blood-based biomarker (P-tau181) in this work.

View Article and Find Full Text PDF

People suffering from a neurodegenerative disease, at a stage still allowing physical activity, encounter more difficulties to access to re-education and rehabilitation care. A trial unit specialized in medical care and rehabilitation (SMR) was created to handle these patients, who suffered a morbid intercurrent event not related to the neurocognitive disorder. The trial unit was created thanks to a dedicated funding from the Brittany Health Regional Agency (ARS) following-up a call for projects in October 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!